For years, patients with C3G and IC-MPGN had few options to stop the progression toward kidney failure. Now a new class of FDA-approved C3 inhibitors that targets the root of the complement system can ...

Hypertension is both a symptom and complication of kidney disease. With C3G and IC-MPGN, blood pressure management is a foundational ‘shield’ that protects kidney function regardless of other ...

Apellis and Sobi's Aspaveli application for C3G and IC-MPGN treatment validated by the EMA, addressing rare kidney diseases. Apellis Pharmaceuticals and Sobi announced that the European Medicines ...

Credit: Apellis. Pegcetacoplan inhibits C3 activation by binding to C3 and its activation fragment C3b, thereby reducing C3 glomerular fragment deposition in patients with C3G and primary IC-MPGN.

WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI ® (pegcetacoplan) as the ...

The U.S. Food and Drug Administration (FDA) on Tuesday accepted and granted Priority Review designation to Apellis Pharmaceuticals, Inc.’s (NASDAQ:APLS) supplemental New Drug Application (sNDA) for ...

The Food and Drug Administration (FDA) has granted Priority Review to pegcetacoplan for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC ...

Robust and clinically meaningful benefits across all three key markers of disease – 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits Consistent ...

EMPAVELI shows significant proteinuria reduction and maintains kidney function in patients with C3G and IC-MPGN; safety profile remains consistent. Apellis Pharmaceuticals and Sobi recently presented ...

80% of patients treated with pegcetacoplan showed a reduction in C3c staining by one or more orders of magnitude of intensity from baseline 40% of patients showed zero staining intensity, indicating ...